New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NDAQ;AAPL;BBRY;HD;GOOG;REGN;SNY;NVO;HEK;GMCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
July 24, 2015
15:06 EDTAAPLEarnings Watch: TV networks report as streaming services gain ground
CBS (CBS), Time Warner (TWX), Viacom (VIA, VIAB), and 21st Century Fox (FOX, FOXA) are among TV network companies expected to report quarterly results over the next several weeks, with Comcast (CMCSA, CMCSK) already having reported before the open on July 23. EXPECTATIONS: Time Warner is expected to report EPS of $1.03 on revenue of $6.9B, CBS is expected to report EPS of 73c on revenue of $3.22B, Viacom is expected to report EPS of $1.47 on revenue of $3.22B, and 21st Century Fox is expected to report EPS of 37c on revenue of $6.48B. LAST QUARTER: CBS, Time Warner, and Fox all reported stronger than expected Q1 results, while Viacom reported higher than expected Q2 EPS but missed on revenue. THIS WEEK'S EARNINGS: On the morning of July 23, Comcast reported Q2 EPS of 84c in line with estimates, and revenue of $18.7B versus expectations for $18.14B. Cable customer relationships for the quarter were up 31,000 to 27.3M, driven by increases in double and triple product relationships. During a subsequent conference call, the company noted that TV viewership continues to be under pressure. NEWS: At Re/code's Code Conference on May 27, CBS CEO Leslie Moonves remarked that his network will "probably" sign up for Apple's (AAPL) rumored TV service, and on June 3, CBS announced that its Showtime network will be offered over the internet as a stand-alone streaming service launching in early July for a monthly price of $10.99, with Apple as its first partner. On July 1, Variety quoted sources as saying Viacom was attempting to entice advertisers by offering to construct social-media and digital extensions of traditional TV ad campaigns as the company seeks to move away from Nielsen-based advertising sales. On July 8, the Wall Street Journal reported that Viacom's Paramount Pictures reached an agreement with AMC (AMC) to accelerate the home release of movies, noting that the company hoped to implement the quickened schedule for all new releases beginning later in the year. On July 17, Re/code reported that Viacom held talks to acquire e-commerce and media company Thrillist Media, according to sources. On June 17, 21st Century Fox named James Murdoch as CEO, with founder and former chairman and CEO Rupert Murdoch appointed executive co-chairman alongside Lachlan Murdoch. The Telegraph reported on June 20 that Fox rejected offers for its stake in Sky (SKYAY) from Vodafone (VOD) and Vivendi (VIVHY), potentially signalling an interest in outright purchasing the rest of Sky, according to the report. More recently, the European Commission announced on July 23 that it delivered a statement of objections to Sky and various film studios owned by Comcast, Viacom, Fox, Time Warner, Disney (DIS), and Sony (SNE), discussing anti-trust concerns due to limitations on country-by-country availability of pay-TV services. STREET RESEARCH: On May 12, Pacific Crest said it believes Apple will launch its TV service before the end of the year, saying the move should benefit TV networks as well as Apple itself. On June 24, Brean Capital said Facebook's (FB) agreement with Time Warner to host premier episodes of certain upcoming shows was "a trend worth following," and possibly indicative of Facebook hosting additional TV content in the future. Also on June 24, FBR Capital contended that Netflix (NFLX) was on pace to have a larger 24-hour audience than all traditional broadcast networks, where ratings are seeing declines on average, according to the research firm. Those comments were followed by a July 10 note on Netflix from Morgan Stanley, saying the subscription streaming service was seeing higher time spent per day than any single broadcast network. Moving away from the Netflix factor, on July 10, JPMorgan said CBS shares looked "very attractive" following a recent selloff, though the company saw a downgrade on July 20 from Pivotal, which cited higher costs of capital among other factors. Finally, Citi upgraded Viacom on July 16 to Neutral, citing recent underperformance in the company's shares heading into earnings season.
15:00 EDTREGNBroader label for PCSK9 drug positive for Regeneron, Amgen, says Deutsche Bank
Subscribe for More Information
14:44 EDTREGN, SNYEsperion slides after FDA assigns indication for rival cholesterol drug
Shares of Esperion Therapeutics (ESPR), a drug company focused on LDL-cholesterol lowering therapies, are sharply lower in afternoon trading after the FDA granted approval for the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 inhibitors. WHAT'S NEW: This afternoon, the FDA announced the approval of Praluent injection, which is a PCSK9 drug marketed by Sanofi (SNY) and Regeneron (REGN). Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol, the FDA indicated. The drug, like Esperion's ETC-1002, seeks to lower patients' cholesterol. PRICE ACTION: In afternoon trading, Esperion shares are down 12% to $84.21. The stock spiked as low as $81.50 immediately after the FDA made its announcement regarding Praulent. Meanwhile, Sanofi shares are fractionally higher and Regeneron shares are halted.
14:20 EDTSNYSanofi drops 0.4% to $53.32 after FDA makes announcement on Praluent
Subscribe for More Information
14:20 EDTSNY, REGNFDA approves Regeneron, Sanofi cholesterol-lowering treatment
The announced the approval of Praluent injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 inhibitors. Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol. Praluent is marketed by Sanofi-Aventis (SNY) and Regeneron (REGN). Shares of Regeneron remain halted.
14:06 EDTREGNRegeneron trading halted, pending news
14:04 EDTGOOGOn The Fly: Weekly technical notes on 'FANG' and divergences
Subscribe for More Information
11:51 EDTAAPLPandora soars after results, guidance top estimates
Shares of internet radio provider Pandora (P) are rising after the company’s second quarter results beat analysts' expectations. The company's third quarter and fiscal year 2015 revenue outlooks also exceeded the consensus. WHAT'S NEW: Thursday after the bell, Pandora reported Q2 adjusted earnings per share of 5c and revenue of $285.56M, easily topping analysts’ consensus estimates of 2c and $283.06M, respectively. Adjusted EBITDA for the quarter was $16.3M, a 29% year-over-year improvement. The company also said that total RPMs increased 24% to $53.91 in Q2, ad RPMs grew 25% to $49.94, ad revenue was $230.9M and said total mobile revenue was $229.7M. For the quarter, total listener hours increased 5% to 5.3B and active listeners were 79.4M at the end of Q2 compared to 76.4M from the same period last year. Looking ahead to Q3, the company forecast revenue of $310M-$315M, slightly ahead of analysts' consensus estimates of $309.2M, and sees Q3 adjusted EBITDA of $25M-$30M. For FY15, Pandora forecast revenue of $1.175B-$1.185B, slightly better than analysts' consensus of $1.17B. Pandora also sees FY15 adjusted EBITDA of $75M-$85M and a tax rate of 30%-35%. WHAT’S NOTABLE: Brian McAndrews, the company's Chief Executive Officer, commented on Apple Music, Apple's (AAPL) recently launched music streaming service. McAndrews said that since the app launched at the end of June, "there was no impact yet" to Pandora. Going forward, McAndrews said that the company "feels really good about our trajectory and competitive position," noting that "there could be some users that experiment with [Apple Music] and there could be some short-term impact." McAndrews does not see any long-term impact from the Apple app. ANALYST REACTION: This morning, analyst commentary has been mixed. Research firm Stifel said Pandora's outlook remains favorable. Stifel said that the company plans to intensify its marketing efforts during the seasonally stronger 2H15 and that the company's outlook for 2H15 has improved following the results. The firm kept a $25 price target and Buy rating on the shares. Another firm, JMP Securities, said Pandora’s mobile trends were encouraging, but said it will stay on sidelines until the company's user trends accelerate and its royalty case concludes. JMP Securities kept a Market Perform rating on the shares. PRICE ACTION: In late morning trading, Pandora rose $2.05, or about 14.8%, to $15.93 on nearly twice its average daily trading volume. Despite today’s advance, the shares have fallen approximately 45% over the past year.
11:02 EDTBBRYBlackBerry CEO says prepared to move past smartphones, Bloomberg says
Subscribe for More Information
10:00 EDTGMCRKeurig Green Mountain volatility elevated into Q3 and outlook
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Subscribe for More Information
08:45 EDTREGNRegeneron cholesterol treatment likely to be approved today, says Bernstein
Bernstein notes that today is the PDUFA day for Regeneron's (REGN) and Amgen's (AMGN) Praluent, which would be the first antibody approved for cholesterol treatment in the U.S. The firm expects the drug to be approved today. After surveying doctors on the drug, Bernstein finds that their attitudes towards it are "remarkably positive." The firm keeps an Outperform rating on Regeneron and a Market Perform rating on Amgen.
07:43 EDTGOOGGoogle, others to create air traffic control for drones, Bloomberg says
Subscribe for More Information
07:21 EDTSNY, REGNRegeneron, Sanofi say CHMP recommends Euro approval of Praluent treatment
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicine Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for the marketing authorization of Praluent, recommending its approval for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9. The European Commission is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September. The CHMP opinion was based on the benefit-risk profile of Praluent, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show consistent, positive results in reducing LDL-C. The U.S. Food and Drug Administration has set a target action date of July 24 for the Biologics License Application of Praluent. The safety and efficacy of Praluent have not been fully evaluated by any other regulatory authority.
07:18 EDTSNY, REGNRegeneron and Sanofi's Praluent recommended for approval in Europe
Regeneron (REGN) and Sanofi (SNY) announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent, recommending its approval for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9. The European Commission is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September.
07:16 EDTREGN, SNYFDA PDUFA Date for Regeneron and Sanofi BLA for Praluent is July 24, 2015
Subscribe for More Information
06:18 EDTGOOGYouTube updates app, to offer VR, Engadget says
Google's YouTube has updated its mobile app, adding Home, Subscriptions, and Account tabs, Engadget reports. Users can watch full-screen vertical videos with just a single tap for the first time. In addition, the redesigned app comes with a set of video creation tools, including the option to trim footage, tint the image with filters, add music, and upload creations within the app. In addition, YouTube said that virtual reality will come to the streaming service with 360-degree video, the report says. Reference Link
06:13 EDTGOOG, AAPLApple removes Nest smart thermostat from online, retail stores, Mashable says
Subscribe for More Information
06:08 EDTGOOGStocks with implied volatility below IV index mean; LOCK GOOG
Subscribe for More Information
July 23, 2015
19:24 EDTGOOG, AAPLWal-Mart's Apple Pay competitor launching soon, Bloomberg says
CurrentC, the mobile payment application funded by Wal-Mart (WMT), Target (TGT), Best Buy (BBY) and others, will see an early trial run next month, Bloomberg reported earlier, citing three people familiar with the situation. A spokesperson for Lowe's (LOW) said the consortium behind the app expects an official launch in Q3, and Bloomberg noted that CurrentC will compete with more "established" offerings such as Apple's (AAPL) Apple Pay and Google's (GOOG) Android Pay. Reference Link
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use